4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pyxis Oncology, Inc. (PYXS) operates in the Biotechnology industry and is headquartered in Boston, United States with about 56 employees. Its market capitalization is roughly $143 million. In the fiscal year ended 2025-12-31, PYXS reported $14M in revenue and ($80M) in net income.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Interactive charts & full statements → Open the PYXS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $14M | $16M | $0M | $0M | — |
| Gross Profit | $12M | $16M | $0M | — | — |
| Operating Income (EBIT) | ($84M) | ($68M) | ($82M) | ($124M) | — |
| Net Income | ($80M) | ($77M) | ($74M) | ($121M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $11M | $0M | $3M | $0M | — |
| Gross Profit | — | $9M | $0M | $3M | $0M | $0M |
| Operating Income (EBIT) | ($24M) | ($18M) | ($24M) | ($20M) | ($23M) | — |
| Net Income | ($23M) | ($18M) | ($22M) | ($18M) | ($21M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $92M | $157M | $174M | $211M | — |
| Total Liabilities | $38M | $36M | $48M | $51M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PYXS viewer.
About TickerBase · Data methodology & sources